Oncology Congress

CME/CE INFORMATION

Oncology Congress

Saturday, December 2, 2023 | Live CME/CE Conference
Broadcast starts at 8:00 AM CT

HOW TO CLAIM CREDIT
In order to obtain your CME/CE certificate(s), please follow the steps below at the conclusion of the event:

Step 1: Log In
Access the event here. At the upper right corner, click Login and enter your username (the email address you used to register for the event) and password.
If you do not know your password, follow the link to reset it.
Step 2: Complete Evaluation(s)
Click the Evaluations tab on the left. You will see a listing of each session. Click the blue Take Evaluation button and complete the evaluation form for each session you attended.
Step 3: View and Print Certificate(s)
After you’ve completed the evaluations, click the blue Print Certificate button to view and print your CME/CE certificates.

Evolving Treatment Paradigms in HER2-Expressing Metastatic Breast Cancer:
Integrating the Latest Evidence in Rural and Underserved Communities

Provided by Talem Health and RME Collaborative:

ACKNOWLEDGEMENT
This initiative is co-supported by independent medical education grants from Astellas; AstraZeneca Pharmaceuticals; Daiichi Sankyo, Inc.; GSK; Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.; and Seagen. This session is supported by independent medical education grants from AstraZeneca Pharmaceuticals and Daiichi Sankyo, Inc.

CREDIT AVAILABLE

Physicians — maximum of 1.0 AMA PRA Category 1 Credit™
Nurses — 1.0 Contact Hour (0.75 contact hour of pharmacotherapy credit)

All other healthcare professionals completing this activity will be issued a statement of participation.

TARGET AUDIENCE
This activity is designed specifically for primary care clinicians, registered nurses, and advanced practice registered nurses who care for patients from rural and underserved areas.

LEARNING OBJECTIVES

Describe how to interpret HER2 testing results to guide treatment selection for patients with HER2-expressing breast cancer
Assess ongoing clinical research evaluating novel agents and treatment strategies for HER2-expressing metastatic breast cancer
Incorporate interprofessional strategies and shared decision-making to reduce breast cancer care disparities in rural and underserved communities
Utilize strategies to improve care access and overcome existing barriers for the management of patients with food allergies residing in rural and underserved communities

FACULTY
Harold J. Burstein, MD, PhD
Professor of Medicine
Harvard Medical School
Medical Oncologist
Dana-Farber Cancer Institute
Boston, MA

Chris Prakash, MD
Director, Quality Services - Texas Oncology
Chair, Medical Oncology Quality - Texas Oncology
President, Texas Society of Clinical Oncology
Medical Director, Texas Oncology - Paris
Paris, TX

JOINT ACCREDITATION STATEMENT

custom image

In support of improving patient care, Talem Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CONTINUING MEDICAL EDUCATION
Talem Health designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour. Designated for 0.75 contact hour of pharmacotherapy credit for Advanced Practice Registered Nurses.

DISCLOSURE OF CONFLICTS OF INTEREST
Talem Health adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All identified conflicts of interest are thoroughly vetted and mitigated according to Talem Health policy. Talem Health is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

All relevant financial relationships have been mitigated.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Faculty
Harold J. Burstein, MD, PhD, has no relevant financial relationships to disclose.

Chris Prakash, MD, has disclosed the following relevant financial relationships: speakers’ bureau/honoraria from Myriad Genetics, Inc.

Planners, Managers, and Reviewer
The Talem Health planners, managers, and reviewer have nothing to disclose.

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Managing Adverse Events Associated With Antibody Drug Conjugates:
Coordinating Care in Rural and Underserved Communities

Provided by Talem Health and RME Collaborative:

CREDIT AVAILABLE

Physicians — maximum of 1.0 AMA PRA Category 1 Credit™
Nurses — 1.0 Contact Hour (1.0 contact hour of pharmacotherapy credit)

All other healthcare professionals completing this activity will be issued a statement of participation.

LEARNING OBJECTIVES

Evaluate common adverse events of antibody-drug conjugate (ADC) therapy and the mechanisms contributing to clinical toxicity
Apply evidence-based strategies and best practices to identify, monitor, and mitigate adverse events associated with ADC therapy
Employ interprofessional strategies for comprehensive, supportive care that meet the complex needs of patients on ADC therapy who reside in rural and underserved areas

FACULTY
Harold J. Burstein, MD, PhD
Professor of Medicine
Harvard Medical School
Medical Oncologist
Dana-Farber Cancer Institute
Boston, MA

JOINT ACCREDITATION STATEMENT

CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour. Designated for 1.0 contact hour of pharmacotherapy credit for Advanced Practice Registered Nurses.

All relevant financial relationships have been mitigated.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Faculty
Harold J. Burstein, MD, PhD, has no relevant financial relationships to disclose.

Chris Prakash, MD, has disclosed the following relevant financial relationships: speakers’ bureau/honoraria from Myriad Genetics, Inc.

Planners, Managers, and Reviewer
The Talem Health planners, managers, and reviewer have nothing to disclose.

Treatment for Advanced Endometrial Cancer:
Addressing Disparities to Improve Quality and Achieve Equity

Provided by Talem Health and RME Collaborative:

ACKNOWLEDGEMENT
This initiative is co-supported by independent medical education grants from Astellas; AstraZeneca Pharmaceuticals; Daiichi Sankyo, Inc.; GSK; Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.; and Seagen. This session is supported by independent medical education grants from GSK and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.

CREDIT AVAILABLE

Physicians — maximum of 1.0 AMA PRA Category 1 Credit™
Nurses — 1.0 Contact Hour (1.0 contact hour of pharmacotherapy credit)

All other healthcare professionals completing this activity will be issued a statement of participation.

LEARNING OBJECTIVES

Summarize the latest clinical trial data on the efficacy and safety of novel therapies for advanced endometrial cancer in both the frontline and subsequent line treatment setting
Apply current guideline recommendations and clinical trial data to tailor treatment selection for patients with advanced endometrial cancer, in both the frontline and subsequent line treatment setting
Determine appropriate molecular and biomarker testing for patients with advanced endometrial cancer
Implement multidisciplinary strategies for improving patient-centered endometrial cancer care in rural and underserved communities

FACULTY
Brian M. Slomovitz, MD, MS
Professor of Obstetrics and Gynecology
Florida International University
Division Director
Mount Sinai Medical Center
Miami, FL/New York, NY

JOINT ACCREDITATION STATEMENT

All relevant financial relationships have been mitigated.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Faculty
Brian M. Slomovitz, MD, MS, has disclosed the following relevant financial relationships: consultant/advisory board member for Aadi Bioscience, AstraZeneca Pharmaceuticals, BioNTech, Clovis Oncology, Genmab, Genetech, Inc., Gilead Sciences, Inc., GOG Foundation, GSK, Incyte Corporation, Karyopharm Therapeutics, Merck & Co., Inc., Myriad Genetics, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Inc., and Seagen.

Chris Prakash, MD, has disclosed the following relevant financial relationships: speakers’ bureau/honoraria from Myriad Genetics, Inc.

Planners, Managers, and Reviewer
The Talem Health planners, managers, and reviewer have nothing to disclose.

Bridging the Gap in Prostate Cancer Care in Rural and Underserved Communities:
An Update on the Latest Advances

Provided by Talem Health and RME Collaborative:

ACKNOWLEDGEMENT
This initiative is co-supported by independent medical education grants from Astellas; AstraZeneca Pharmaceuticals; Daiichi Sankyo, Inc.; GSK; Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.; and Seagen. This session is supported by an independent medical education grant from Astellas.

CREDIT AVAILABLE

Physicians — maximum of 1.0 AMA PRA Category 1 Credit™
Nurses — 1.0 Contact Hour (0.75 contact hour of pharmacotherapy credit)

All other healthcare professionals completing this activity will be issued a statement of participation.

LEARNING OBJECTIVES

Describe risk stratification approaches for patients diagnosed with prostate cancer
Evaluate the efficacy and safety of evolving treatment options for nonmetastatic hormone-sensitive prostate cancer, metastatic hormone-sensitive prostate cancer, and nonmetastatic castration-resistant prostate cancer
Integrate clinical evidence and guidelines into treatment plans for patients with prostate cancer
Apply strategies including coordination of care and shared decision-making to overcome barriers to prostate cancer care in rural and underserved settings

FACULTY
Alicia K. Morgans, MD, MPH
Associate Professor of Medicine
Harvard Medical School
Medical Director, Survivorship Program
Dana-Farber Cancer Institute
Boston, MA

JOINT ACCREDITATION STATEMENT

All relevant financial relationships have been mitigated.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Faculty
Alicia K. Morgans, MD, MPH, has disclosed the following relevant financial relationships: consultant/advisory board member for Astellas, AstraZeneca Pharmaceuticals, Bayer, Exelixis, Inc., Janssen Pharmaceuticals, Lantheus, Merck & Co., Inc., Myovant Sciences, Myriad Genetics, Novartis Pharmaceuticals Corporation, Pfizer, Inc., Sanofi, and Telix Pharmaceuticals.

Chris Prakash, MD, has disclosed the following relevant financial relationships: speakers’ bureau/honoraria from Myriad Genetics, Inc.

Planners, Managers, and Reviewer
The Talem Health planners, managers, and reviewer have nothing to disclose.

Evolving Treatment Paradigms in Hepatocellular Carcinoma:
Applying the Latest Evidence in Rural and Underserved Communities

Provided by Talem Health and RME Collaborative:

ACKNOWLEDGEMENT
This initiative is co-supported by independent medical education grants from Astellas; AstraZeneca Pharmaceuticals; Daiichi Sankyo, Inc.; GSK; Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.; and Seagen. This session is supported by an independent medical education grant from Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.

CREDIT AVAILABLE

Physicians — maximum of 1.0 AMA PRA Category 1 Credit™
Nurses — 1.0 Contact Hour (0.75 contact hour of pharmacotherapy credit)

All other healthcare professionals completing this activity will be issued a statement of participation.

LEARNING OBJECTIVES

Assess the efficacy and safety of immunotherapies and combination therapy approaches for unresectable hepatocellular carcinoma (HCC)
Integrate clinical evidence and current guideline recommendations on immunotherapies and combination therapy into treatment plans for patients with unresectable HCC
Implement interprofessional strategies for reducing disparities in care access and treatment for HCC in rural and underserved settings

FACULTY
Ghassan K. Abou-Alfa, MD, MBA
Attending Physician
Memorial Sloan Kettering Cancer Center
New York, NY

JOINT ACCREDITATION STATEMENT

All relevant financial relationships have been mitigated.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Faculty
Ghassan K. Abou-Alfa, MD, MBA, has disclosed the following relevant financial relationships: research/grant support from Agenus, Inc., Arcus Biosciences, AstraZeneca Pharmaceuticals, BioNTech, BMS, Elicio Therapeutics, Inc., Genentech, Inc./Roche, Helsinn, Parker Institute for Cancer Immunotherapy, Pertzye - Digestive Care, Inc., Puma Biotechnology, Inc., QED Therapeutics, and Yiviva; consultant/advisory board member for AstraZeneca Pharmaceuticals, Autem Therapeutics, Berry Genomics, BioNTech, Boehringer Ingelheim, BMS, Eisai, Inc., Exelixis, Inc., Genentech, Inc./Roche, Incyte Corporation, Ipsen, Merck & Co., Inc., Merus, Neogene Therapeutics, Novartis Pharmaceuticals Corporation, Servier Pharmaceuticals, Tempus, Vector Pharma, and Yiviva.

Chris Prakash, MD, has disclosed the following relevant financial relationships: speakers’ bureau/honoraria from Myriad Genetics, Inc.

Planners, Managers, and Reviewer
The Talem Health planners, managers, and reviewer have nothing to disclose.

CONTACT US

For questions about this activity, please contact RME Collaborative (a division of Talem Health) at 800-913-9370 or cme@cmeruralhealth.com.

MEDIA
Internet activity

COMPUTER SYSTEM REQUIREMENTS

System checker: Must meet all requirements of BroadcastMed Live Events Platform
Operating system: Windows or Macintosh
Supported browsers: HTML5-capable browser – Internet Explorer, Google Chrome, Mozilla Firefox, Safari, Microsoft Edge, Opera
Hardware: computer, smartphone, or tablet
Broadband Internet connection: high-speed connection preferable

FEE INFORMATION
There is no fee for this educational activity.

COPYRIGHT
©RME Collaborative, a division of Talem Health, LLC. All Rights Reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Talem Health, LLC is prohibited.